Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020-2023): a longitudinal multicentre real-world study - PubMed
6 hours ago
- #Control-IQ technology
- #Type 1 diabetes
- #Pediatric endocrinology
- Study evaluates long-term efficacy and safety of Control-IQ technology in children aged 0.5-5 years with type 1 diabetes in Italy (2020-2023).
- 253 children were followed for 18 months, divided into age groups 0.5-5 years (131) and 6-10 years (122).
- Significant improvements in Time in Range (TIR) and Time in Tight Range (TITR) were observed within the first 6 months and sustained through 18 months.
- No significant differences in glycemic outcomes between the two age groups.
- Higher parental education level was associated with better TIR, while longer duration between diagnosis and Control-IQ initiation correlated with lower TITR.
- Adverse events were rare, with only one episode of severe hypoglycemia in the older group and one DKA episode in the younger group.
- Findings support potential off-label use of Control-IQ in young children under supervision.
- No specific funding was received for this study.